ArticleAlzheimer's research & therapy2021
COVID-19 in adults with dementia: clinical features and risk factors of mortality-a clinical cohort study on 125 patients.
Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Meta-analysis of the serum/plasma proteome identifies significant associations between COVID-19 with Alzheimer's/Parkinson's diseases.Journal of neurovirology · 2024Pooled it
- Risk factors for 30-day COVID-19 mortality among people living with dementia in Alberta, Canada: a retrospective cohort study.BMC geriatrics · 2025Article
- The Influence of SARS-CoV-2 Infection on the Development of Selected Neurological Diseases.International journal of molecular sciences · 2024Review
- Predictors of COVID‑19‑associated mortality among hospitalized elderly patients with dementia.Experimental and therapeutic medicine · 2023Article
- Risk factors and outcomes of delirium in hospitalized older adults with COVID-19: A systematic review and meta-analysis.Aging and health research · 2023Review
- Links between COVID-19 and Alzheimer's Disease-What Do We Already Know?International journal of environmental research and public health · 2023Review
- Older patients with COVID-19 and neuropsychiatric conditions: A study of risk factors for mortality.Brain and behavior · 2022Observational
- Dementia prevalence, a contextual factor associated with SARS-CoV-2 in veterans affairs community living centers.Journal of the American Geriatrics Society · 2022Article
- Animal models for COVID-19: advances, gaps and perspectives.Signal transduction and targeted therapy · 2022Review
- One-Year Report of COVID-19 Impact on Geriatric Patients: a Bio-Psycho-Social Approach.Canadian geriatrics journal : CGJ · 2022Review
- Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2022Review
- Parkinson's Disease and SARS-CoV-2 Infection: Particularities of Molecular and Cellular Mechanisms Regarding Pathogenesis and Treatment.Biomedicines · 2022Review
- Incidence and Outcomes of SARS-CoV-2 Infection in Older Adults Living with Dementia: A Population-Based Cohort Study.Journal of Alzheimer's disease : JAD · 2022Article
- Baseline clinical features of COVID-19 patients, delay of hospital admission and clinical outcome: A complex relationship.PloS one · 2022Article
- Neurological Complications of COVID-19 in the Elderly.Neuroscience and behavioral physiology · 2022Article
- Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson's Disease?Brain sciences · 2021Review
- Prediction of COVID-19-related Mortality and 30-Day and 60-Day Survival Probabilities Using a Nomogram.Journal of Korean medical science · 2021Article
- Hyperactivated RAGE in Comorbidities as a Risk Factor for Severe COVID-19-The Role of RAGE-RAS Crosstalk.Biomolecules · 2021Review
- COVID-19 Case Fatality and Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2021Article
- SARS-CoV-2, the Angiotensin Converting Enzyme 2 (ACE2) Receptor and Alzheimer's disease.Journal of Alzheimer's disease & Parkinsonism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is limited evidence on the characteristics and outcome of patients with dementia hospitalised for novel coronavirus infection (COVID-19).
methodWe conducted a prospective study in 2 gerontologic COVID units in Paris, France, from March 14, 2020, to May 7, 2020. Patients with dementia hospitalised for confirmed COVID-19 infection were systematically enrolled. A binary logistic regression analysis was performed to identify factors associated with mortality at 21 days.
resultsWe included 125 patients. Median age was 86 (IQI 82-90); 59.4% were female. Most common causes of dementia were Alzheimer's disease, mixed dementia and vascular dementia. 67.2% had ≥ 2 comorbidities; 40.2% lived in a long-term care facility. The most common symptoms at COVID-19 onset were confusion and delirium (82.4%), asthenia (76.8%) and fever (72.8%) before polypnea (51.2%) and desaturation (50.4%). Falls were frequent at the initial phase of the disease (35.2%). The fatality rate at 21 days was 22.4%. Chronic kidney disease and CRP at admission were independent factors of death. Persisting confusion, mood and behavioural disorders were observed in survivors (19.2%).
conclusionCOVID-19 in demented individuals is associated with severe outcome in SARS-CoV-2 infection and is characterised by specific clinical features and complications, with confusion and delirium at the forefront. COVID-19 testing should be considered in front of any significant change from baseline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.